Zobrazeno 1 - 10
of 18
pro vyhledávání: '"F G, Haluska"'
Autor:
Terence R. Flotte, G Jiang, Susan V. Westmoreland, S Fee, Philip W. Hinds, F G Haluska, Nageatte Ibrahim, V K Goel, F S Haluska, M Singhal
Publikováno v:
Oncogene. 28:2289-2298
BRAF, a cellular oncogene and effector of RAS-mediated signaling, is activated by mutation in approximately 60% of melanomas. Most of these mutations consist of a V600E substitution resulting in constitutive kinase activation. Mutant BRAF thus repres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::461e6b9ce497b31eeff737d5a4189327
https://doi.org/10.1038/onc.2009.95
https://doi.org/10.1038/onc.2009.95
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes
Autor:
D B, Greenberg, E, Jonasch, M A, Gadd, B F, Ryan, J R, Everett, A J, Sober, M A, Mihm, K K, Tanabe, M, Ott, F G, Haluska
Publikováno v:
Cancer. 89(2)
The use of a high dose regimen of interferon-alpha-2b (IFN) has recently been demonstrated to benefit patients with resected high risk melanoma. The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::27ebc97b12e1a7ec4afed0e4058ab8c6
https://pubmed.ncbi.nlm.nih.gov/10918166
https://pubmed.ncbi.nlm.nih.gov/10918166
Autor:
E, Jonasch, U N, Kumar, G P, Linette, F S, Hodi, R J, Soiffer, B F, Ryan, A J, Sober, M C, Mihm, H, Tsao, R G, Langley, B A, Cosimi, M A, Gadd, K K, Tanabe, W, Souba, H A, Haynes, R, Barnhill, R, Osteen, F G, Haluska
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(3)
We performed an analysis of toxicity and survival in stage III melanoma patients receiving adjuvant interferon alfa-2b (IFN). This was a retrospective single-arm analysis of 40 patients with stage III melanoma who received (IFN) administered at maxim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a89d105b50a7c0b2353e487f0fbe956
https://pubmed.ncbi.nlm.nih.gov/10882326
https://pubmed.ncbi.nlm.nih.gov/10882326
Autor:
F G, Haluska, P S, Multani
Publikováno v:
Cancer chemotherapy and biological response modifiers. 18
In melanoma, conventional therapies, especially cytotoxic chemotherapies, have proven unsatisfactory. Although a variety of agents have been tested singly and in combination, recent randomized studies have demonstrated that the response rates observe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c2eb5b2f82d45fca9eefbe33fb9bf4f
https://pubmed.ncbi.nlm.nih.gov/10800498
https://pubmed.ncbi.nlm.nih.gov/10800498
Publikováno v:
Cancer research. 59(1)
A novel p53-related gene, p73, was recently isolated and cytogenetically mapped to chromosome region 1p36. Functionally, p73 expression induces p21waf and suppresses tumor cell growth. We mapped p73 using radiation hybrids and localized the gene to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::df32c113b030eea751eea8c39959a0f5
https://pubmed.ncbi.nlm.nih.gov/9892203
https://pubmed.ncbi.nlm.nih.gov/9892203
Publikováno v:
Cancer research. 58(1)
Mutations in genes that lie in the retinoblastoma pathway have been implicated in the pathogenesis of many tumor types. Two critical components that determine progression from G1 to S include p16/CDKN2A and CDK4. Alterations in p16/CDKN2A have been w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44ee5f2f8957d5dff46d0cb8438e2ece
https://pubmed.ncbi.nlm.nih.gov/9426066
https://pubmed.ncbi.nlm.nih.gov/9426066
Publikováno v:
International journal of cancer. 72(2)
A candidate murine tumor-suppressor gene, Mom1, has been identified as the secretory phospholipase A2 (GDB nomenclature: PLA2G2A) gene. Evidence suggests that PLA2G2A functions as a tumor-suppressor because mice lacking PLA2G2A expression demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3d10de10e1e42744677cf1fa790f4b18
https://pubmed.ncbi.nlm.nih.gov/9219842
https://pubmed.ncbi.nlm.nih.gov/9219842
Autor:
J F, Flores, G J, Walker, J M, Glendening, F G, Haluska, J S, Castresana, M P, Rubio, G C, Pastorfide, L A, Boyer, W H, Kao, M L, Bulyk, R L, Barnhill, N K, Hayward, D E, Housman, J W, Fountain
Publikováno v:
Cancer research. 56(21)
Although homozygous deletions of the cyclin-dependent kinase inhibitor 2 gene p16INK4a on 9p21 have been reported frequently in metastatic melanoma cell lines, and intragenic mutations within the p16INK4a gene have been detected in familial melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ad9faeedfba984b7f5ca56d41d686e3
https://pubmed.ncbi.nlm.nih.gov/8895759
https://pubmed.ncbi.nlm.nih.gov/8895759
Autor:
J A, Reed, F, Loganzo, C R, Shea, G J, Walker, J F, Flores, J M, Glendening, J K, Bogdany, M J, Shiel, F G, Haluska, J W, Fountain
Publikováno v:
Cancer research. 55(13)
Sporadic and familial malignant melanoma susceptibility has been linked to defects in the chromosomal region 9p21. Recently, a putative 9p21 tumor suppressor gene, the cyclin dependent kinase inhibitor 2 (CDKN2) or p16 gene, has been shown to be dele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b2d0cbbfb285b4bb9f89ee073ee8c27
https://pubmed.ncbi.nlm.nih.gov/7796391
https://pubmed.ncbi.nlm.nih.gov/7796391
Autor:
F G, Haluska, D E, Housman
Publikováno v:
Cancer surveys. 25
The study of the molecular basis for sporadic and inherited melanoma has rapidly moved forward over the past several years. The crucial observation that chromosome 9p21 abnormalities occurred with high frequency in sporadic melanomas, coupled with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74adf2202491c029aa7446e1d348d7a5
https://pubmed.ncbi.nlm.nih.gov/8718523
https://pubmed.ncbi.nlm.nih.gov/8718523